drugset / Trial / NCT03665155
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to test 89Zr-DFO-daratumumab, a new imaging agent, to demonstrate its safety and ability to take pictures of the myeloma.
Timeline
- Start
- 2018-09-05
- Primary completion
- 2020-04-20
- Completion
- 2020-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89Zr-daratumumab | Monoclonal antibody | 3 mg | — |
| Subject | 89Zr-daratumumab | Monoclonal antibody | 37 mbq | — |
| Subject | 89Zr-daratumumab | Monoclonal antibody | 50 mg | — |
| Subject | 89Zr-daratumumab | Monoclonal antibody | 74 mbq | — |
| Subject | 89Zr-daratumumab | Monoclonal antibody | 185 mbq | — |